The role of long noncoding RNA CRNDE in normal physiology and cancer
长链非编码RNA CRNDE在正常生理和癌症中的作用
基本信息
- 批准号:10715065
- 负责人:
- 金额:$ 48.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AllelesAlternative SplicingAnimal ModelAnimalsBindingBiogenesisBiologyBone Marrow TransplantationBreedingCRISPR interferenceCancer BiologyCancer PatientCause of DeathCell LineCell NucleolusCell ProliferationCell modelCharacteristicsCodeCollaborationsColorectal NeoplasmsConstitutionConstitutionalCustomCytoplasmDataDevelopmentDiagnosisDiseaseElementsGenesGenetic EngineeringGenomicsGrowthHematopoieticHematopoietic NeoplasmsHumanImpairmentKnockout MiceKnowledgeLengthLibrariesMalignant - descriptorMalignant NeoplasmsMapsMediatingMolecularMolecular Mechanisms of ActionMusNucleotidesPancreasPathogenesisPathway interactionsPatientsPhenocopyPhenotypePhysiologicalPhysiologyPlayPredispositionProductionProliferatingProteinsProteomicsRNARenal Cell CarcinomaRenal carcinomaResearchResolutionResourcesRibosomal RNARibosomesRoleShwachman-Diamond syndromeTestingTissuesTranscriptTranslationsTumor PromotionUnited StatesUntranslated RNAVariantcancer cellcancer typedifferential expressioneffective therapyexperienceexperimental studyin vivoknock-downloss of functionmouse modelnovelnovel therapeutic interventionoverexpressionpatient derived xenograft modelprematurepreventregeneration modelskeletal abnormalitytherapeutic targettissue injurytissue regenerationtranscriptome sequencingtumortumor growthtumor progressionurologic
项目摘要
PROJECT SUMMARY
A growing body of evidence indicates that long noncoding RNAs (lncRNAs), a diverse class of non-protein-
coding transcripts >200 nucleotides in length, play important roles in the initiation and progression of cancer.
LncRNAs have been proposed to regulate all cancer hallmarks, but, in the vast majority of cases, their
molecular mechanisms of action remain poorly understood. This knowledge gap is a major impediment
towards realizing the potential of lncRNAs as therapeutic targets in cancer and other diseases. As in many
human malignancies, lncRNAs are frequently dysregulated in renal cell carcinoma (RCC). RCC is the most
common type of kidney cancer and the most lethal malignant urological tumor, with approximately 70,000 new
cases diagnosed annually in the United States. To date, most genomic studies of RCC (and other cancers)
have focused on identifying disease-associated alterations of protein-coding genes. Our understanding of the
molecular pathways regulated by lncRNAs in RCC, and the functional roles of these transcripts in this
malignancy, remains limited. We mined RNA-seq data from RCC patients to identify a set of 805 lncRNAs that
are commonly overexpressed in this tumor type. We generated a custom CRISPR interference (CRISPRi)
library targeting these lncRNAs and performed screens in multiple RCC cell lines to identify lncRNAs that are
essential for RCC cell proliferation. These experiments revealed that the lncRNA Colorectal neoplasia
differentially expressed (CRNDE) is required for growth of all tested RCC cell lines. Although this lncRNA has
been shown to be overexpressed and is associated with poor patient survival in RCC and other types of
cancer, its molecular function remains unclear. We identified a critical region of CRNDE that is necessary for
RCC cell proliferation and we identified proteins that interact with this sequence. We also generated novel
genetically-engineered alleles in mice that enable constitutional or conditional deletion of critical Crnde
sequences. In this proposal, we will leverage our new understanding of this lncRNA, and the novel resources
we have generated, in order to dissect the molecular function of CRNDE and define its role in normal
physiology and in RCC pathogenesis in vivo. These experiments will take advantage of our extensive
experience, and that of our collaborators, in evaluating noncoding RNA functions and RCC biology using
cellular and animal models. Successful completion of the proposed research will address two major knowledge
gaps in the fields of RNA biology and cancer biology: 1) our limited understanding of the molecular
mechanisms-of-action of lncRNAs; and 2) how these mechanisms are co-opted by cancer cells to promote
tumor growth, particularly in RCC. We anticipate that the principles revealed by these studies will be broadly
applicable to our understanding of the roles of other lncRNAs in cancer cells and may set the stage for
developing therapeutics that target CRNDE or the pathways it controls.
项目摘要
越来越多的证据表明,长链非编码RNA(lncRNA),一类不同的非蛋白质-
长度>200个核苷酸的编码转录物在癌症的发生和发展中起重要作用。
已经提出lncRNA调节所有癌症标志,但是,在绝大多数情况下,它们的表达与肿瘤的发生有关。
作用的分子机制仍然知之甚少。这种知识差距是一个主要障碍
实现lncRNA作为癌症和其他疾病治疗靶点的潜力。因为在许多
在人类恶性肿瘤中,lncRNA在肾细胞癌(RCC)中经常失调。RCC是最
肾癌是一种常见的肾癌,也是最致命的恶性泌尿系统肿瘤,每年约有70,000例新发
美国每年确诊的病例数。迄今为止,大多数RCC(和其他癌症)的基因组研究
一直专注于识别与疾病相关的蛋白质编码基因的改变。我们理解
肾癌中lncRNA调控的分子途径,以及这些转录本在这一过程中的功能作用。
恶性肿瘤,仍然有限。我们从RCC患者中挖掘RNA-seq数据,以确定一组805种lncRNA,
通常在这种肿瘤中过度表达。我们生成了定制的CRISPR干扰(CRISPRi)
靶向这些lncRNA的文库,并在多个RCC细胞系中进行筛选,以鉴定
对RCC细胞增殖至关重要。这些实验表明,lncRNA结肠直肠肿瘤
差异表达(CRNDE)是所有测试的RCC细胞系的生长所需要的。尽管这种lncRNA
已被证明是过度表达,并与肾癌和其他类型的肿瘤患者的生存率低有关。
癌症,其分子功能仍不清楚。我们确定了CRNDE的一个关键区域,
RCC细胞增殖,我们鉴定了与该序列相互作用的蛋白质。我们还创造了新的
在小鼠中进行基因工程改造的等位基因,使关键基因的组成性或条件性缺失成为可能。
序列的在这项提案中,我们将利用我们对这种lncRNA的新理解,以及新的资源,
为了剖析CRNDE的分子功能,并确定其在正常人中的作用,
生理学和体内RCC发病机制。这些实验将利用我们广泛的
经验,以及我们的合作者,在评估非编码RNA功能和RCC生物学使用
细胞和动物模型。成功完成拟议的研究将解决两个主要知识
RNA生物学和癌症生物学领域的差距:1)我们对分子生物学的理解有限,
lncRNA的作用机制;以及2)这些机制如何被癌细胞吸收以促进肿瘤细胞的生长。
肿瘤生长,特别是在RCC中。我们预计,这些研究揭示的原则将广泛地
适用于我们对癌细胞中其他lncRNA作用的理解,并可能为
开发针对CRNDE或其控制的途径的治疗方法。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Target-directed microRNA degradation regulates developmental microRNA expression and embryonic growth in mammals.
- DOI:10.1101/gad.350906.123
- 发表时间:2023-07-01
- 期刊:
- 影响因子:10.5
- 作者:Jones, Benjamin T.;Han, Jaeil;Zhang, He;Hammer, Robert E.;Evers, Bret M.;Rakheja, Dinesh;Acharya, Asha;Mendell, Joshua T.
- 通讯作者:Mendell, Joshua T.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua T Mendell其他文献
Tumors line up for a letdown
肿瘤排队等待失望。
- DOI:
10.1038/ng0709-768 - 发表时间:
2009-07-01 - 期刊:
- 影响因子:29.000
- 作者:
Joshua T Mendell - 通讯作者:
Joshua T Mendell
Joshua T Mendell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua T Mendell', 18)}}的其他基金
The intersection of RNA biology and tumor biology
RNA生物学与肿瘤生物学的交叉点
- 批准号:
8953055 - 财政年份:2015
- 资助金额:
$ 48.96万 - 项目类别:
The intersection of RNA biology and tumor biology
RNA生物学与肿瘤生物学的交叉点
- 批准号:
10213661 - 财政年份:2015
- 资助金额:
$ 48.96万 - 项目类别:
The intersection of RNA biology and tumor biology
RNA生物学与肿瘤生物学的交叉点
- 批准号:
9125799 - 财政年份:2015
- 资助金额:
$ 48.96万 - 项目类别:
Functional Evaluation of microRNAs in Pancreatic Neoplasia
microRNA 在胰腺肿瘤中的功能评估
- 批准号:
8464662 - 财政年份:2013
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
7915972 - 财政年份:2009
- 资助金额:
$ 48.96万 - 项目类别:
Functional Evaluation of microRNAs in Pancreatic Neoplasia
microRNA 在胰腺肿瘤中的功能评估
- 批准号:
7651550 - 财政年份:2009
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
8026614 - 财政年份:2007
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
8712397 - 财政年份:2007
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
8578048 - 财政年份:2007
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
7766253 - 财政年份:2007
- 资助金额:
$ 48.96万 - 项目类别:
相似海外基金
Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
- 批准号:
488788 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
Operating Grants
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
- 批准号:
10638347 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
- 批准号:
10717440 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
- 批准号:
10577186 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
- 批准号:
10749474 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
- 批准号:
10673458 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
- 批准号:
2884151 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
- 批准号:
10660668 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
- 批准号:
2239056 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
- 批准号:
468851650 - 财政年份:2022
- 资助金额:
$ 48.96万 - 项目类别:
Research Grants